Benha大学的突破：随机对照试验显示伊维菌素可有效治疗COVID-19
埃及Benha大学和团队的首席研究员
最近完成了一项名为“伊维菌素治疗和预防COVID-19大流行的功效和安全性”的临床试验。
现在可在预印服务器上获得的结果令人鼓舞。
艾哈迈德·埃尔加扎尔（Ahmed Elgazzar）博士和一个团队，包括来自Benha大学的其他研究人员，
一项经过精心设计的临床试验再次证明，将抗寄生虫药物伊维菌素添加到护理标准中实际上是治疗COVID-19患者的有效药物。
埃及队宣布
与仅使用羟氯喹加标准疗法相比，该研究药物可降低死亡率。
而且，团队现在宣布
伊维菌素的早期使用是
不仅有效控制COVID-19感染
而且还可以预防并有助于改善潜在的致命细胞因子风暴。
卫生监管部门和研究机构应承认
这种有效且经济的药物的越来越多的证据，并立即投资于美国等更先进的经济体。
The Study
With accumulating evidence of
not only the efficacy of Ivermectin
but also the prominent role being played by Egyptian research centers,
this Benha University-based study sought to investigate Ivermectin from a few different important angles.
The team designed a
multicenter,
randomized,
controlled clinical trial (RCCT)
involving 600 subjects,
including 400 COVID-19 diagnosed patients and
200 health care (e.g., health professionals & workers) and
household contacts at Benha and Kafrelsheikh University hospitals.
The study commenced
on June 8 and concluded on September 15, 2020.
They evaluated Ivermectin plus the standard of care for this region, which includes azithromycin, vitamin C, Zinc, Lactoferrin and Acetylcysteine and prophylactic or therapeutic anticoagulation
Additionally and importantly, the investigational team
probed the prophylaxis benefit of health care and/or household contacts in comparison to Hydroxychloroquine plus standard treatment.
Involving 600 subjects, the study design split the patients by 400 symptomatic patients confirmed with COVID-19;
200 health care and house hold contacts distributed over 6 groups including the following –
The study team
reported that those patients receiving Ivermectin reported “substantial recovery of laboratory investigations” coupled with “significant reduction in RT-PCR conversion days.”
They report that those patients receiving Ivermectin experienced a “substantial improvement and reduction in mortality rate.”
TrialSite summarizes the results: